lactoferrin and Schistosomiasis-mansoni

lactoferrin has been researched along with Schistosomiasis-mansoni* in 1 studies

Other Studies

1 other study(ies) available for lactoferrin and Schistosomiasis-mansoni

ArticleYear
Evaluation of faecal lactoferrin as a morbidity biomarker in Schistosoma mansoni infection.
    Tropical medicine & international health : TM & IH, 2022, Volume: 27, Issue:12

    Lactoferrin is an 80 KDa iron-binding glycoprotein that plays a significant role in the innate immune system and is considered to be an important microbicide molecule. This study aimed to assess the concentration of lactoferrin in Schistosoma mansoni-infected cases before and after praziquantel treatment.. A cross-sectional study was carried out on 250 individuals aged from 5 to 30 years. Stool samples were examined for the presence of parasitic infections using Kato-Katz and formalin ethyl acetate techniques. All S. mansoni-positive cases were treated with praziquantel and stool samples were recollected 21 days later. Faecal lactoferrin level was determined before and after treatment.. The prevalence of S. mansoni infection was 14.4%. Among 36 participants infected with S. mansoni, the cure rate was 91.7%. A statistically significant difference in the mean lactoferrin level before and after treatment was detected (1648.95 pg/ml ± 656.5 vs. 1162.8 pg/ml ± 356.8). This difference was statistically significant in the middle and older age groups, in males and in the absence of coinfection with other parasites.. Lactoferrin could be a promising biomarker associated with S. mansoni infection, however, it could not be used to assess the severity of infection.

    Topics: Adolescent; Adult; Animals; Biomarkers; Child; Child, Preschool; Cross-Sectional Studies; Feces; Humans; Lactoferrin; Male; Praziquantel; Prevalence; Schistosoma mansoni; Schistosomiasis mansoni; Young Adult

2022